ABVC BioPharma, Inc. (ABVC)

US — Healthcare Sector
Peers: RVPH  GRCE  LVTX  PDSB  ATNM  JUNS  TVRD  FGEN  LTRN  XLO 

Automate Your Wheel Strategy on ABVC

With Tiblio's Option Bot, you can configure your own wheel strategy including ABVC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ABVC
  • Rev/Share 0.0343
  • Book/Share 0.6232
  • PB 5.4006
  • Debt/Equity 0.1154
  • CurrentRatio 0.6258
  • ROIC -0.284

 

  • MktCap 40573243.0
  • FreeCF/Share -0.0886
  • PFCF -19.6874
  • PE -15.6639
  • Debt/Assets 0.0657
  • DivYield 0
  • ROE -0.647

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About ABVC BioPharma, Inc. (ABVC)

  • IPO Date 2004-11-10
  • Website https://www.abvcpharma.com
  • Industry Biotechnology
  • CEO Uttam Yashwant Patil
  • Employees 16
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.